Dosing & Uses
Dosage Forms & Strengths
0.2 mg IM/IV q2-4hr PRN; not to exceed 5 doses, THEN 0.2-0.4 mg PO q6-8hr PRN for 2-7 days
Administer IV only in emergency because of potential for Hypertension & CVA
Administer over >1 minute and monitor BP
Refractory Cluster Headache (Off-label)
0.2 mg PO q6-8hr, not to exceed 6 months
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Transient chest pain
Allergic phenomena including shock
Nervous system: Cerebrovascular accident, paraesthesia
Cardiovascular: Ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block
(All not necessarily unanimous): Hypertension, heart disease, toxemia, pregnancy, hypersensitivity, mitral valve stenosis, prolonged use
Cases of threatened spontaneous abortion
Avoid during breastfeeding
Second or third stage of labor prior to placenta delivery: complications such as captivation of placenta may occur; avoid accidental injection to newborn babies
Increased risk of myocardial ischemia and infarction with coronary artery disease or risk factors for coronary artery disease
Sepsis, hepatic impairment, renal impairment, peripheral vascular disease
Prolonged use may cause pleuropulmonary, cardiac or retroperitoneal fibrosis
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excreted in milk; adverse effect on nursing infant; may inhibit lactation; not recommended
Wait at least 12 hours after last dose to breastfeed
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Produces vasoconstriction to increase strength, duration, & frequency of uterine contraction which in turn impedes uterine blood flow
Bioavailability: 60% (PO); 78% (IM)
Peak Plasma Time: 30 min
Peak Plasma Concentration: 3 ng/mL
Onset: uterine contractions are usually initiated within 5-15 min following oral administration, within 2-5 min after IM injection, & immediately following IV injection
Duration: 3 hr (PO); 3hr (IM); 45 min (IV)
Excretion: Urine and feces
- Initial phase: 1-5 min
- Terminal phase: 0.5-2 hr
Give IV only in emergency because of potential for HTN & CVA
Give over >1 min & monitor BP & uterine contractions
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.